Radiprodil

N/A

Report date: 2026/03/10 20:00:16
NME

Base Information

Drug NameRadiprodil
Drug Alias NameRadiprodilum雷拉地尔雷迪罗地RGH-896UCB-3491
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate [NMDA] receptor subunit epsilon 2 antagonists
TargetsGlutamate [NMDA] receptor subunit epsilon 2
Therapy Area/IndicationsNeurodevelopmental DisordersDiabetic NeuropathiesMalformations of Cortical Development +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesGedeon Richter Plc
China Registration ClassN/A

Develop Information

Active CompaniesAngelini PharmaGrin Therapeutics Inc
Inactive CompaniesUcb Biopharma SprlGedeon Richter LtdForest Laboratories Inc
Active IndicationsNeurodevelopmental DisordersMalformations of Cortical DevelopmentHepatic Insufficiency +[4] 
Inactive IndicationsDiabetic NeuropathiesSpasms, InfantileNervous System Diseases

Other Information

ATC CodeN/A
Related LinksN/A